Donor-specific circulating cell free DNA as a noninvasive biomarker of graft injury in heart transplantation

Considerable effort has been exerted to develop noninvasive diagnostic biomarkers that might replace or reduce the need to perform endomyocardial biopsies. In this context, graft DNA circulating on transplant recipients has been proposed as a potential biomarker of organ rejection or cellular graft injury. We propose a digital PCR (dPCR) method based on the amplification of ten specific InDels sufficiently sensitive to detect small amounts of specific donor circulating DNA diluted on the host cell free DNA (cfDNA). We obtained 23 informative mismatches from 30 host and donor organ biopsy pairs. Patients without heart-related complications showed a high increase in the specific genomic marker levels during the first 24 h after transplantation that dropped to the basal levels on days 3–4 post-surgery. In contrast, patients with complications presented a significantly lagged decay pattern from day one after transplantation. A specific donor cfDNA increase was detected in one patient two days before rejection diagnosis, diminishing the basal levels after successful immunotherapy. A cfDNA increase was also observed during graft injury due to heart damage. These results suggest that cfDNA monitoring of transplanted patients may be a useful tool to detect and probably anticipate graft rejection. •All patients showed a high increase in the specific genomic marker after transplantation.•CfDNA from patients without heart-related complications decreased after transplantation.•Patients with complications showed a lagged decay pattern from day one after transplantation.•A specific donor cfDNA increase was detected in one patient two days before rejection diagnosis.•A cfDNA increase was also observed during graft injury due to heart damage.